Muscle News and Research

RSS

Nektar commences dosing in NKTR-192 Phase 1 clinical study for treatment of acute pain

Nektar Therapeutics announced today that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the pharmacokinetics and safety of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate.

2 Apr 2012

Allowing the heart to rest can reverse structural changes in myocytes after heart failure

Structural changes in heart muscle cells after heart failure can be reversed by allowing the heart to rest, according to research at Imperial College London. Findings from a study in rats published today in the European Journal of Heart Failure show that the condition's effects on heart muscle cells are not permanent, as has generally been thought. The discovery could open the door to new treatment strategies.

2 Apr 2012

Studies use three genes to reprogram fibroblasts into myocytes

The latest research developments to reprogram scar tissue resulting from myocardial infarction (MI) into viable heart muscle cells, were presented at the Frontiers in CardioVascular Biology (FCVB) 2012 meeting, held 30 March to 1 April at the South Kensington Campus of Imperial College in London.

2 Apr 2012

RNA binding motif protein 20 regulates titin splicing

Cardiomyopathy comprises a deterioration of the heart muscle that affects the organ's ability to efficiently pump blood through the body. Previously researchers have tied forms of the disease to the alternative splicing of titin, a giant protein that determines the structure and biomechanical properties of the heart, but the molecular mechanism remained unknown.

2 Apr 2012

Study provides new information on why A-T disease attacks the brain

Rutgers scientists think they have found a way to prevent and possibly reverse the most debilitating symptoms of a rare, progressive childhood degenerative disease that leaves children with slurred speech, unable to walk, and in a wheelchair before they reach adolescence.

2 Apr 2012

Study shows how fat cells can protect the body against diabetes

In a finding that may challenge popular notions of body fat and health, researchers at Beth Israel Deaconess Medical Center (BIDMC) have shown how fat cells can protect the body against diabetes. The results may lead to a new therapeutic strategy for preventing and treating type 2 diabetes and obesity-related metabolic diseases, the authors say.

2 Apr 2012

Starvation during childhood may increase risk of heart complications

Russians born during the Leningrad Siege in World War II, which was responsible for some of the greatest losses of civilian life in history, are giving scientists new strategies to identify people who experienced intrauterine growth restriction (IUGR) and starvation during childhood at greatest risk of developing long term heart complications.

31 Mar 2012

Top-line results from Shire's SPD476 phase 3 trial on diverticulitis

Shire plc, the global specialty biopharmaceutical company, today announced top-line results of the PREVENT2 trial, a phase 3 investigational study of once-daily SPD476, MMX mesalamine in patients with a history of diverticulitis.

31 Mar 2012

Intronix launches Myoguide Needle EMG Guided Injection System

Great things come in small packages, or at least that's what leading neurologists, physiatrists and clinicians are now discovering with the revolutionary Myoguide Needle EMG Guided Injection System. The breakthrough technology, which has just received 510(k) clearance from the United States Food and Drug Administration, gives practitioners a superior way to deliver targeted injections for musculoskeletal pain, spasticity, fibromyalgia, and even cosmetics.

31 Mar 2012

USAID NTD Program funding cut by nearly 25% in proposed FY13 budget

"The United States Government has played a major role in ensuring that patients with certain [neglected tropical diseases (NTDs)] receive urgently needed treatments through the [USAID] NTD Program, while simultaneously being the largest funder of basic research for NTDs through the National Institutes of Health,"

30 Mar 2012

Cancer cells grow and proliferate more robustly when exposed to human cells

New research from the Technion-Israel Institute of Technology Rappaport Faculty of Medicine and Research Institute and the Rambam Medical Center may lead to the development of new methods for controlling the growth of cancer, and perhaps lead to treatments that will transform cancer from a lethal disease to a chronic, manageable one, similar to AIDS.

30 Mar 2012

Cyberplasm could pinpoint diseases within the human body

A tiny prototype robot that functions like a living creature is being developed which one day could be safely used to pinpoint diseases within the human body.

30 Mar 2012

New synthetic small molecules could treat obesity, diabetes and sleep disorders

Scientists from the Florida campus of The Scripps Research Institute have synthesized a pair of small molecules that dramatically alter the core biological clock in animal models, highlighting the compounds' potential effectiveness in treating a remarkable range of disorders-including obesity, diabetes, high cholesterol, and serious sleep disorders.

30 Mar 2012

Sitting more than four hours a day could raise risk of dying early: Study

According to Australian researchers spending less time sitting could boost longevity. Their study of more than 220,000 NSW residents found the longer you spend sitting down the greater your risk of dying early, even if you otherwise do regular exercise.

29 Mar 2012

FDA extends review period for Almirall and Forest Labs' aclidinium bromide NDA

Forest Laboratories, Inc. and Almirall, S.A. announced today that the U.S. Food and Drug Administration (FDA) will require a three-month extension to complete its review of the data supporting the New Drug Application (NDA) for aclidinium bromide, a new long-acting antimuscarinic for the maintenance treatment of Chronic Obstructive Pulmonary Disease.

29 Mar 2012

Daiichi Sankyo, NGM to discover and develop new treatments for diabetes

Daiichi Sankyo Company, Ltd. and NGM Biopharmaceuticals, Inc. announced today that they have entered into a research collaboration and license agreement to discover and develop novel therapeutics that modulate beta-cell regeneration for the treatment of diabetes.

29 Mar 2012

Researchers describe unexpected role of p75NTR in type 2 diabetes

Scientists at the Gladstone Institutes have discovered a key protein that regulates insulin resistance-the diminished ability of cells to respond to the action of insulin and which sets the stage for the development of the most common form of diabetes. This breakthrough points to a new way to potentially treat or forestall type 2 diabetes, a rapidly growing global health problem.

29 Mar 2012

Positive results from Allergan's BOTOX Phase III trials on idiopathic overactive bladder

Allergan, Inc. today announced that two Phase III clinical trials of BOTOX (onabotulinumtoxinA) as a potential treatment option for patients with idiopathic overactive bladder met their pre-specified primary endpoints.

29 Mar 2012

New MRI method to test effectiveness of baking soda against breast cancer

A University of Arizona study that looks to improve the way doctors can measure the effectiveness of drinking baking soda to fight breast cancer has received a $2 million grant from the National Institutes of Health.

28 Mar 2012

Invasive strategy benefits patients with myotonic dystrophy type 1 neuromuscular disorder

Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.

28 Mar 2012